Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy

Renal Failure

Volumn 30, Issue 10, 2008, Pages 1023-1033

  Saniye, Sen ^a   Mehmet, Kanter ^a   Sedat, Ustundag ^a   Cevat, Aktas ^a   Dogutan, Haluk ^a   Omer, Yalcin ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Diabetic nephropathy; Irbesartan; Quinapril; Renal function; TGF 1; Ultrastructure

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; IRBESARTAN; QUINAPRIL; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETOGENESIS; DRUG EFFECT; FEMALE; GENERAL CONDITION IMPROVEMENT; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; KIDNEY CAPSULE; KIDNEY FUNCTION; KIDNEY TUBULE BASEMENT MEMBRANE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 57049112199     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802495248     Document Type: Article

References (46)

1. Kreisberg JI, Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int. 1993;43:109.
2. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 1999;56:1627-1637.
3. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int. 2000;58:S93-S98.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. New Engl J Med. 1993;329:1456-1462.
5. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-coverting enzyme inhibition and angiotensin receptor antagonist in diabetic spontaneously hypertensive rats. Clin Sci. 2001;100:591-599.
6. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med. 2001;345:870-878.
7. Reams GP, Bauer JH. Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney. Cardiovasc Drugs Ther. 1990;4:207-219.
8. Linz W, Becker RHA, Scholkens BA, Wiemer G, Keil M, Langer KH. Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney Int. 1998;54:2037-2044.
9. Velasquez MT, Striffler JS, Abraham AA, Michaelis OE, Salbert N. Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. Hypertension 1997;30:1232-1237.
10. Ono H, Ono Y, Frochlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1996;27:176-183.
11. Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive renal nephropathy. Am J Kidney Dis. 1999;34:626-632.
12. Nakaya H, Sasamura H, Kitamura Y, et al. Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens Res. 1999;22:303-312.
13. Bergstrom G, Johansson I, Stevenson KM, Kett MM, Anderson WP. Perindopril treatment affects both preglomerular renal vascular lumen dimensions and in vivo responsiveness to vasoconstrictors in spontaneously hypertensive rats. Hypertension 1998;31:1007-1013.
14. Verseput GH, Koomans HA, Braam B, Weening JJ, Provoost AP. ACE inhibition delays development of terminal renal failure in the presence of severe albuminuria. Am J Kidney Dis. 2000;35:202-210.
15. Kanter M, Meral I, Yener Z, Ozbek H, Demir H. Partial regeneration/proliferation of the β-cells in the islets of Langerhans by Nigella sativa L. in streptozocin-induced diabetic rats. Tohoku J Exp Med. 2003;20:213-219.
16. Kanter M, Coskun O, Korkmaz A, Oter S. Effects of Nigella sativa on oxidative stress and β-cell damage in streptozocin-induced diabetic rats. Anat. Rec. 2004;279:685-691.
17. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
18. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kid Dis. 1997;29:153-163.
19. Ziyadeh FN. Renal tubular membrane and collagen type IV in diabetes mellitus. Kidney Int. 1993;43:114-120.
20. Mauer SM, Steffes MW, Ellis EN, et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74:1143-1155.
21. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370-379.
22. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol. 2004;286:F1039-F1045.
23. Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol. 2003;14:873-880.
24. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol. 2005;288:F1183-F1190.
25. Zimpelmann J, Kumar D, Levine DZ, et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int. 2000;58:2320-2330.
26. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulosclerosis by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
27. Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int. 1987;31:S108-S111.
28. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-b expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431-2437.
29. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. New Engl J Med. 1994;331:1286-1292.
30. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest. 1996;74:991-1003.
31. Singh R, Alavi N, Singh AK, Leehey DJ. Role of antgiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999;48:2066-2073.
32. Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10:2382-2391.
33. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002;39:129-134.
34. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251-287.
35. 2receptor - a matter of love and hate. Peptides 2005;26:1401-1409.
36. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999;33:1237-1242.
37. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol. 1999;276:F39-F45.
38. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J Am Soc Nephrol. 1998;9:1716-1722.
39. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000;321: 1440-1444.
40. Sengul AM, Altunas Y, Kurklu A, et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract. 2006;71:210-219.
41. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease: A randomised controlled trial. Lancet 2003;361:117-124.
42. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 2004;30:498-505.
43. Unger T, Jakobsen A, Heroys J, Ralph A, Rees T, Shaw M. Targeting cardiovascular protection: The concept of dual renin-angiotensin system control. Medscape J Med. 2008;10:S4.
44. de Cavanagh EM, Ferder L, Toblli JE, et al. Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes. Am J Physiol Heart Circ Physiol. 2008;294:H456-H465.
45. Wu Y, Ouyang JP, Zhou YF, Wu K, Zhao DH, Wen CY. Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. Sheng Li Xue Bao. 2004;56:539-549.
46. Registry of nephrology, dialysis and transplantation in Turkey. Nobel Tip Kitabevi, Istanbul, 2000.